Holding(s) in Company

RNS Number : 5809M
Shield Therapeutics PLC
12 January 2023
 

 

 

TR-1: Standard form for notification of major holdings

 


NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)  i


 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are at- tached ii :

 

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights


An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights

x

Other (please specify) iii :


3. Details of person subject to the notification obligation iv

Name

W. Health L.P. ("Inventages")

City and country of registered office (if applicable)

The Bahamas

4. Full name of shareholder(s) (if different from 3.) v

Name

CGWL Nominees Limited

City and country of registered office (if applicable)

London, UK

5. on the was or reached vi :

 

6 January 2023

6. Date on which issuer notified (DD/MM/YYYY):

11 January 2023

7. Total positions of person(s) subject to the notification obligation


% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial instru- ments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A +

8.B) vii

Resulting situation on the date on which threshold was

crossed or reached

 

9.56%

 

0%

 

9.56%

 

56,008,541

Position of previous notification (if applicable)

 

21.76%

 

0%

 

21.76%









 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

9.56%

0%











SUBTOTAL 8. A

56,008,541

9.56%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

 

Type of financial in- strument

 

Expiration date x

 

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument is exercised/converted.

 

% of voting rights

















SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date x

Exercise/ Conversion Pe- riod xi

Physical or cash Settlement xii

Number of voting rights

 

% of voting rights




















SUBTOTAL 8.B.2



 

 

 





 

 

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv


 

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold


























 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held


 

 




 

Place of completion

The Bahamas

Date of completion

11 January 2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBTMITMTTBBJJ
UK 100

Latest directors dealings